TMS Co., Ltd.
Stock Price Chart
2026/09/30 18:46 UpdatedPrice Trend
2026/09/30 18:46 UpdatedPrice & Trading Details
2026/09/30 18:46 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/09/01Shareholder Composition
Updated 2026/09/01Financial Performance
2026/09/27 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | |
|---|---|
| Income Statement | |
| Revenue | ¥1,947M |
| Gross Profit | - |
| Operating Income | ¥1,136M |
| Pretax Income | ¥1,136M |
| Net Income | ¥1,077M |
| EPS | ¥53.36 |
| Operating Margin | 58.34% |
| Balance Sheet | |
| Total Assets | ¥2,740M |
| Total Equity | ¥2,453M |
| Total Liabilities | ¥287M |
| Cash | ¥2,598M |
| Interest-bearing Debt | - |
| Equity Ratio | 89.53% |
| D/E Ratio | 0.00 |
| Cash Flow | |
| Operating CF | ¥1,262M |
| Investing CF | -¥17M |
| Financing CF | ¥246M |
| Free CF | ¥1,253M |
| Efficiency | |
| ROE | 43.90% |
| ROA | 39.30% |
Latest IR Information
-
Notification of Submission of Clinical Trial Notification for Early Phase II Clinical Trial of TMS-008 for Acute Kidney Injury
Submitted a clinical trial notification to PMDA to initiate the domestic early Phase II clinical trial of TMS-008. The target population is patients at risk of acute kidney injury after cardiac surgery. The trial is double-blind, randomized, placebo-controlled, dose-escalation, and...
Read more -
PMDA-facing advisory for the domestic first-half Phase II trial of TMS-008 has ended
The in-person advisory with PMDA regarding the domestic first-half Phase II trial of TMS-008 has ended. Preparations such as site selection and submission of the clinical trial notification will proceed as a start of the trial. The cost impact is...
Read more -
Notice of Large Exercise, Completion of Exercise, and Monthly Exercise Status for the 10th Stock Acquisition Rights (with Exercise Price Adjustment Clause)
Disclosure of the completion of exercises and monthly exercise status during the exercise period for the 10th stock acquisition rights (2026/09/01–2026/09/08). At the start of the period, 868,200 shares were issued; cumulative exercises until September 8 were 6,428 shares; unexercised...
Read more -
Notice on Monthly Exercise Status of the 10th Stock Acquisition Rights (with Exercise Price Adjustment Clause)
During the month, 1,245,300 shares were issued, 12,453 stock options were exercised, and the exercise rate was 3.09%. As of the end of the previous month, unexercised rights totaled 21,135 units, decreasing to 8,682 by month-end. Exercise dates were mainly...
Read more -
(Correction) Notice regarding partial corrections to the 'Interim 2Q 2026 Fiscal Year Earnings Presentation Materials'
Notice of partial correction to the Interim 2Q 2026 fiscal year earnings presentation materials. The corrections involve deleting the sections framed in red; corrected materials will be posted on the website. An attached document allows confirmation of the correction details.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥620
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. In addition, the company has a collaboration with Hokkaido University to evaluate the potential of the drug candidate compounds as novel drugs. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.
